Coronavirus (COVID-19) updates for UC San Diego Health patients and visitors. Learn More

Menu
Search

FDA Approves “Icy Fire” Drug Based on UC San Diego Researcher’s Findings

 

March 05, 2008  |  

A drug to treat a rare, inherited disease that causes rash, fever, chills and joint pain in patients when they are exposed to cold temperatures has been approved by the U.S. Food and Drug Administration (FDA).  The therapy, ARCALYST™ (rilonacept), marketed by Regeneron Pharmaceuticals, is based on a discovery by Hal Hoffman, M.D., associate professor of medicine at UC San Diego School of Medicine.

ARCALYST has received marketing approval for the treatment Cryopyrin-Associated Periodic Syndromes (CAPS), including Familial Cold Auto-inflammatory Syndrome (FCAS) and Muckle-Wells Syndrome (MWS) in adults and children 12 and older.   CAPS is a group of rare, inherited, auto-inflammatory conditions characterized by life-long, recurrent symptoms of rash, fever and chills, joint pain, eye pain and fatigue.  Symptoms can be triggered at any time by exposure to cooling temperatures, stress or exercise.

FCAS is an “orphan” hereditary disease that affects only about 300 people in the United States, 90 percent of them tracing their ancestry to a single person who came to America in the 1600s.   Hoffman’s team first identified the genetic basis of the disease: a mutation that causes alterations in the protein they named cryopyrin – which means “icy fire” – because cold triggers fever in patients. 

“This is a perfect example of  research that was bedside to bench…and back,” said Hoffman, who has studied FCAS by drawing blood samples at different family reunions held through the United States and interviewing hundreds of patients across the country about their symptoms.  “The approval of this drug represents a major advance in the treatment of CAPS patients.  I hope it will bring increased awareness of this rare disease, which is frequently misdiagnosed.”

Cryopyrin regulates the release of interleukin-1, an important mediator of fever and systemic inflammation during the body’s initial immune response.  Researchers found that alterations in cryopyrin lead to over-production of Il-1, which is inhibited by ARCALYST.

In clinical studies at 20 sites including UC San Diego, patients treated with the drug experienced greater improvement in overall symptoms than patients treated with a placebo.  Regeneron expects to launch ARCALYST, its first commercial product, by the end of March.  It is the only therapy currently approved for patients with CAPS.
                                                      # # #

Media Contact: Debra Kain, 619-543-6163, ddkain@ucsd.edu




Media Contact

Share This Article


Related News

3/26/2020
Researchers at University of California San Diego School of Medicine are launching a pair of studies to answer critical questions regarding the roles COVID-19 may play in breast milk and pregnancy.
3/24/2020
Researchers at four University of California Health medical centers have begun recruiting participants for a Phase II clinical trial to investigate the safety and efficacy of treating adult patients w ...
3/20/2020
Partnering with five diagnostics manufacturers, UC San Diego is significantly ramping up testing for COVID-19, projecting capacity to complete up to 1,500 tests daily within two to three weeks.
3/18/2020
New study finds gene therapy improved cardiac, muscle and liver function in Danon disease mouse models.



Follow Us